Intensive insulin therapy in severely burned pediatric patients: A Prospective randomized trial

Marc G. Jeschke, Gabriela A. Kulp, Robert Kraft, Celeste Finnerty, Ron Mlcak, Jong Lee, David Herndon

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Rationale: Hyperglycemia and insulin resistance have been shown to increase morbidity and mortality in severely burned patients, and glycemic control appears essential to improve clinical outcomes. However, to date no prospective randomized study exists that determines whether intensive insulin therapy is associated with improved post-burn morbidity and mortality. Objectives: To determine whether intensive insulin therapy is associated with improved post-burn morbidity. Methods: Atotal of 239 severely burned pediatric patients with burns over greater than 30% of their total body surface area were randomized (block randomization 1:3) to intensive insulin treatment (n = 60) or control (n = 179). Measurements and Main Results: Demographics, clinical outcomes, sepsis, glucose metabolism, organ function, and inflammatory, acute-phase, and hypermetabolic responses were determined. Demographics were similar in both groups. Intensive insulin treatment significantly decreased the incidence of infections and sepsis compared with controls (P < 0.05). Furthermore, intensive insulin therapy improved organ function as indicated by improved serum markers, DENVER2 scores, and ultrasound (P < 0.05). Intensive insulin therapy alleviated post-burn insulin resistance and the vast catabolic response of the body (P < 0.05). Intensive insulin treatment dampened inflammatory and acute-phase responses by deceasing IL-6 and acute-phase proteins compared with controls (P < 0.05). Mortality was 4% in the intensive insulin therapy group and 11% in the control group (P = 0.14). Conclusions: In this prospective randomized clinical trial, we showed that intensive insulin therapy improves post-burn morbidity. Clinical trial registered with www.clinicaltrials.gov (NCT00673309).

Original languageEnglish (US)
Pages (from-to)351-359
Number of pages9
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume182
Issue number3
DOIs
StatePublished - Aug 1 2010

Fingerprint

Insulin
Pediatrics
Burns
Morbidity
Acute-Phase Reaction
Therapeutics
Insulin Resistance
Mortality
Sepsis
Demography
Acute-Phase Proteins
Body Surface Area
Group Psychotherapy
Random Allocation
Hyperglycemia
Interleukin-6
Randomized Controlled Trials
Biomarkers
Clinical Trials
Prospective Studies

Keywords

  • Burn
  • Insulin
  • Morbidity
  • Pediatric
  • Sepsis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Intensive insulin therapy in severely burned pediatric patients : A Prospective randomized trial. / Jeschke, Marc G.; Kulp, Gabriela A.; Kraft, Robert; Finnerty, Celeste; Mlcak, Ron; Lee, Jong; Herndon, David.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 182, No. 3, 01.08.2010, p. 351-359.

Research output: Contribution to journalArticle

Jeschke, Marc G. ; Kulp, Gabriela A. ; Kraft, Robert ; Finnerty, Celeste ; Mlcak, Ron ; Lee, Jong ; Herndon, David. / Intensive insulin therapy in severely burned pediatric patients : A Prospective randomized trial. In: American Journal of Respiratory and Critical Care Medicine. 2010 ; Vol. 182, No. 3. pp. 351-359.
@article{605e30b649484538b1c113ab349c456e,
title = "Intensive insulin therapy in severely burned pediatric patients: A Prospective randomized trial",
abstract = "Rationale: Hyperglycemia and insulin resistance have been shown to increase morbidity and mortality in severely burned patients, and glycemic control appears essential to improve clinical outcomes. However, to date no prospective randomized study exists that determines whether intensive insulin therapy is associated with improved post-burn morbidity and mortality. Objectives: To determine whether intensive insulin therapy is associated with improved post-burn morbidity. Methods: Atotal of 239 severely burned pediatric patients with burns over greater than 30{\%} of their total body surface area were randomized (block randomization 1:3) to intensive insulin treatment (n = 60) or control (n = 179). Measurements and Main Results: Demographics, clinical outcomes, sepsis, glucose metabolism, organ function, and inflammatory, acute-phase, and hypermetabolic responses were determined. Demographics were similar in both groups. Intensive insulin treatment significantly decreased the incidence of infections and sepsis compared with controls (P < 0.05). Furthermore, intensive insulin therapy improved organ function as indicated by improved serum markers, DENVER2 scores, and ultrasound (P < 0.05). Intensive insulin therapy alleviated post-burn insulin resistance and the vast catabolic response of the body (P < 0.05). Intensive insulin treatment dampened inflammatory and acute-phase responses by deceasing IL-6 and acute-phase proteins compared with controls (P < 0.05). Mortality was 4{\%} in the intensive insulin therapy group and 11{\%} in the control group (P = 0.14). Conclusions: In this prospective randomized clinical trial, we showed that intensive insulin therapy improves post-burn morbidity. Clinical trial registered with www.clinicaltrials.gov (NCT00673309).",
keywords = "Burn, Insulin, Morbidity, Pediatric, Sepsis",
author = "Jeschke, {Marc G.} and Kulp, {Gabriela A.} and Robert Kraft and Celeste Finnerty and Ron Mlcak and Jong Lee and David Herndon",
year = "2010",
month = "8",
day = "1",
doi = "10.1164/rccm.201002-0190OC",
language = "English (US)",
volume = "182",
pages = "351--359",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3",

}

TY - JOUR

T1 - Intensive insulin therapy in severely burned pediatric patients

T2 - A Prospective randomized trial

AU - Jeschke, Marc G.

AU - Kulp, Gabriela A.

AU - Kraft, Robert

AU - Finnerty, Celeste

AU - Mlcak, Ron

AU - Lee, Jong

AU - Herndon, David

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Rationale: Hyperglycemia and insulin resistance have been shown to increase morbidity and mortality in severely burned patients, and glycemic control appears essential to improve clinical outcomes. However, to date no prospective randomized study exists that determines whether intensive insulin therapy is associated with improved post-burn morbidity and mortality. Objectives: To determine whether intensive insulin therapy is associated with improved post-burn morbidity. Methods: Atotal of 239 severely burned pediatric patients with burns over greater than 30% of their total body surface area were randomized (block randomization 1:3) to intensive insulin treatment (n = 60) or control (n = 179). Measurements and Main Results: Demographics, clinical outcomes, sepsis, glucose metabolism, organ function, and inflammatory, acute-phase, and hypermetabolic responses were determined. Demographics were similar in both groups. Intensive insulin treatment significantly decreased the incidence of infections and sepsis compared with controls (P < 0.05). Furthermore, intensive insulin therapy improved organ function as indicated by improved serum markers, DENVER2 scores, and ultrasound (P < 0.05). Intensive insulin therapy alleviated post-burn insulin resistance and the vast catabolic response of the body (P < 0.05). Intensive insulin treatment dampened inflammatory and acute-phase responses by deceasing IL-6 and acute-phase proteins compared with controls (P < 0.05). Mortality was 4% in the intensive insulin therapy group and 11% in the control group (P = 0.14). Conclusions: In this prospective randomized clinical trial, we showed that intensive insulin therapy improves post-burn morbidity. Clinical trial registered with www.clinicaltrials.gov (NCT00673309).

AB - Rationale: Hyperglycemia and insulin resistance have been shown to increase morbidity and mortality in severely burned patients, and glycemic control appears essential to improve clinical outcomes. However, to date no prospective randomized study exists that determines whether intensive insulin therapy is associated with improved post-burn morbidity and mortality. Objectives: To determine whether intensive insulin therapy is associated with improved post-burn morbidity. Methods: Atotal of 239 severely burned pediatric patients with burns over greater than 30% of their total body surface area were randomized (block randomization 1:3) to intensive insulin treatment (n = 60) or control (n = 179). Measurements and Main Results: Demographics, clinical outcomes, sepsis, glucose metabolism, organ function, and inflammatory, acute-phase, and hypermetabolic responses were determined. Demographics were similar in both groups. Intensive insulin treatment significantly decreased the incidence of infections and sepsis compared with controls (P < 0.05). Furthermore, intensive insulin therapy improved organ function as indicated by improved serum markers, DENVER2 scores, and ultrasound (P < 0.05). Intensive insulin therapy alleviated post-burn insulin resistance and the vast catabolic response of the body (P < 0.05). Intensive insulin treatment dampened inflammatory and acute-phase responses by deceasing IL-6 and acute-phase proteins compared with controls (P < 0.05). Mortality was 4% in the intensive insulin therapy group and 11% in the control group (P = 0.14). Conclusions: In this prospective randomized clinical trial, we showed that intensive insulin therapy improves post-burn morbidity. Clinical trial registered with www.clinicaltrials.gov (NCT00673309).

KW - Burn

KW - Insulin

KW - Morbidity

KW - Pediatric

KW - Sepsis

UR - http://www.scopus.com/inward/record.url?scp=77956623049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956623049&partnerID=8YFLogxK

U2 - 10.1164/rccm.201002-0190OC

DO - 10.1164/rccm.201002-0190OC

M3 - Article

C2 - 20395554

AN - SCOPUS:77956623049

VL - 182

SP - 351

EP - 359

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 3

ER -